Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: BioDrugs. 2017 Dec;31(6):473–481. doi: 10.1007/s40259-017-0247-0

Figure 1. Schema of the currently used strategies to generate universal off the shelf or allogeneic CART cells.

Figure 1

1) CART cells derived from original hematopoietic donors for patients relapsing after allogeneic transplantation; 2) Selection for non- alloreactive T cells to generate CART cells (such as virus specific CART cells) 3) Use of alternative effector cells, e.g. macrophages and NK cells; 4) Gene-edited CART. E.g.: TALEN technology used to generate TCR negative, CD52-negative CART cells; Zinc-finger nucleases and CRISPR-Cas9 to knock out the TCR and HLA; The CAR construct is directly delivered into the TCR locus with CRISPR-Cas9 and an AAV template, generating TCR-negative CART cells. The ideal universal CART should be HLA and TCR negative and include non-classical HLA to avoid NK cell lysis. It should also include a suicide system to control for potential toxicity.